278 related articles for article (PubMed ID: 15112269)
1. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Hu Q; Dey AL; Yang Y; Shen Y; Jilani IB; Estey EH; Kantarjian HM; Giles FJ; Albitar M
Cancer; 2004 May; 100(9):1884-91. PubMed ID: 15112269
[TBL] [Abstract][Full Text] [Related]
2. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Hock BD; McKenzie JL; Patton NW; Drayson M; Taylor K; Wakeman C; Kantarjian H; Giles F; Albitar M
Cancer; 2006 May; 106(10):2148-57. PubMed ID: 16598754
[TBL] [Abstract][Full Text] [Related]
5. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
6. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D
Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Hock BD; McKenzie JL; Patton WN; Haring LF; Yang Y; Shen Y; Estey EH; Albitar M
Cancer; 2003 Oct; 98(8):1681-8. PubMed ID: 14534885
[TBL] [Abstract][Full Text] [Related]
8. Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.
Keith T; Araki Y; Ohyagi M; Hasegawa M; Yamamoto K; Kurata M; Nakagawa Y; Suzuki K; Kitagawa M
Br J Haematol; 2007 May; 137(3):206-15. PubMed ID: 17408459
[TBL] [Abstract][Full Text] [Related]
9. [Expression of angiogenic factors and their clinical significances in acute myeloid leukemia].
Wang Y; Xiao ZJ; Liu P; Peng Z; Han ZC
Ai Zheng; 2004 Nov; 23(11 Suppl):1423-7. PubMed ID: 15566649
[TBL] [Abstract][Full Text] [Related]
10. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Albitar M; Johnson M; Do KA; Day A; Jilani I; Pierce S; Estey E; Kantarjian H; Keating M; Verstovsek S; O'brien S; Giles FJ
Leukemia; 2007 Mar; 21(3):480-8. PubMed ID: 17215857
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
[TBL] [Abstract][Full Text] [Related]
13. [Change of vascular endothelial growth factor and its receptors expression in acute myeloid leukemia before and after treatment].
Zhang JQ; Wang JK; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2004 Feb; 25(2):100-2. PubMed ID: 14990052
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients.
de Bont ES; Fidler V; Meeuwsen T; Scherpen F; Hählen K; Kamps WA
Clin Cancer Res; 2002 Sep; 8(9):2856-61. PubMed ID: 12231527
[TBL] [Abstract][Full Text] [Related]
15. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptors for vascular endothelial growth factor (sVEGFR1/sVEGFR2) in infantile hemangioma.
Przewratil P; Sitkiewicz A; Andrzejewska E
Growth Factors; 2010 Dec; 28(6):417-25. PubMed ID: 20854187
[TBL] [Abstract][Full Text] [Related]
17. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
19. Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia.
Lee CY; Tien HF; Hu CY; Chou WC; Lin LI
Br J Cancer; 2007 Oct; 97(7):877-82. PubMed ID: 17848952
[TBL] [Abstract][Full Text] [Related]
20. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Klimek VM; Fircanis S; Maslak P; Guernah I; Baum M; Wu N; Panageas K; Wright JJ; Pandolfi PP; Nimer SD
Clin Cancer Res; 2008 Feb; 14(3):826-32. PubMed ID: 18245545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
